No Data
No Data
Atai Life Sciences CEO Talks Successful Phase 1 Trial of IV Psilocin Formulation – ICYMI | NASDAQ:ATAI, ETR:9VC
Atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
Atai Life Sciences Co-CEO Says Initial Results From ELE-101 Show Promise in Treating Depression | NASDAQ:ATAI, ETR:9VC
Express News | Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences
Atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, With Initial Results From Phase 1 and First Patients Dosed in Phase 2a
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The
Atai Life Sciences Optimistic as IV Psilocin Shows Promise in Treating Depression in Early Trial | NASDAQ:ATAI, ETR:9VC
No Data